BioWorld
-
Hahn steers clear of controversy in Senate hearing for FDA job
-
Aravive apperceived: Invariant ovarian outcome backs first phase Ib results
-
With a howl and a series A, Werewolf Therapeutics is born
-
SK invests in Standigm for AI-based drug development
-
Ph Pharma and Immunome to collaborate in antibody-drug conjugates
-
Chi-Med submits NDA for surufatinib in China for advanced non-pancreatic NET
-
Prominent Chinese immunologist embroiled in data fabrication scandal
-
Myovant's relugolix shines in phase III prostate cancer study
-
Crispr Therapeutics’ interim data: First two patients functionally cured by CRISPR/Cas9 therapy?
BioWorld MedTech
-
Tissium raises €39M to expand surgical sealant, add 3D printed and drug-delivery applications
-
FDA clears Carestream’s Dual-Energy radiography technology, Focus 35C detector
-
Hahn steers clear of controversy in Senate hearing for FDA job
-
SK invests in Standigm for AI-based drug development
-
Prominent Chinese immunologist embroiled in data fabrication scandal
-
BioWorld MedTech's Orthopedics Extra
-
Bioventrix scores breakthrough device status for Revivent Tc heart failure system
-
Medtronic shines in Q2, with diabetes seeing a boost internationally
-
Device accessories are eligible for FDA safer technologies program
BioWorld Asia
-
China looking to close gap in cell therapy market; CAR T development advancing fast
-
SL Bigen secures ₩3B from Yuhan for CAR-NK therapy
-
FDA approval of Shionogi antibacterial sets stage for move into new market
-
Is China ready for first-in-class? Not quite, but we must go ahead with innovation, experts say
-
Too many PD-1s? Facing a competitive landscape, Chinese firms seek ways to stand out
-
Foreign pharma can leverage China’s regulatory pragmatism, patients and lower trial costs
-
Aslan's varlitinib clinical study for BTC patients failed to meet primary endpoints
-
Akeso closes $150M series D to advance first-in-class bispecific antibodies
-
Tot Biopharm raises $61M on HKEX, co-develops antibody with Harbour
